Glucocorticoids in clinical oncology.

Glucocorticoids have been used in clinical oncology for more than three decades. Their anti-inflammatory action plays a major role in their clinical applications in oncology. The incidence and severity of side effects depend on the total dose and the duration of therapy, but optimal dosages for these drugs have not been determined. Little is known about other risk factors for toxicity. Prednisone and dexamethasone, the two most commonly used drugs, are well absorbed orally and share quantitatively similar pharmacokinetic values. No definite relationship is known between the glucocorticoid blood level (total and unbound concentration) and therapeutic effect. Glucocorticoids play a major role in the treatment of lymphoproliferative disorders and breast cancer, and they often succeed in palliating common symptoms in advanced cancer.

[1]  D. Weissman.  Glucocorticoid treatment for brain metastases and epidural spinal cord compression: a review. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Walsh,et al.  Controlling symptoms in advanced cancer. , 1988, British medical journal.

[3]  M. Greaves,et al.  Potential value of vintristine‐adriamycin‐dexamethasone combination chemotherapy (VAD) in refractory and rapidly progressive myeloma , 1987, European journal of haematology.

[4]  E. Begg,et al.  The pharmacokinetics of corticosteroid agents , 1987, The Medical journal of Australia.

[5]  B. Chir.,et al.  Cancer pain. , 1987, The Medical clinics of North America.

[6]  B. Barlogie,et al.  High-dose glucocorticoid treatment of resistant myeloma. , 1986, Annals of internal medicine.

[7]  D. Tormey,et al.  Pulmonary toxicity induced by mitomycin C is highly responsive to glucocorticoids , 1986, Cancer.

[8]  C. Gallant,et al.  Oral glucocorticoids and their complications. A review. , 1986, Journal of the American Academy of Dermatology.

[9]  J. Connors,et al.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.

[10]  L. Dodds.  THE CONTROL OF CANCER CHEMOTHERAPY‐INDUCED NAUSEA AND VOMITING , 1985, Journal of clinical and hospital pharmacy.

[11]  B. Ponder,et al.  Interaction modulation through arrays of clustered methyl-arginine protein modifications , 2018, Life Science Alliance.

[12]  R. Gale,et al.  Recent advances in the biology and treatment of acute lymphoblastic leukemia in adults. , 1984, The New England journal of medicine.

[13]  D. Stover,et al.  Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids. , 1984, Chest.

[14]  G. Rosner,et al.  BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. , 1984, Annals of internal medicine.

[15]  G. Donovitz,et al.  Antiemetic efficacy of high-dose corticosteroids and droperidol in cisplatin-induced emesis: a controlled trial with droperidol and metoclopramide. , 1984, Gynecologic oncology.

[16]  D. Mitchell,et al.  Do corticosteroids really alter mood? , 1984, Postgraduate medical journal.

[17]  B. Barlogie,et al.  Effective treatment of advanced multiple myeloma refractory to alkylating agents. , 1984, The New England journal of medicine.

[18]  C. Bloomfield.  Glucocorticoid receptors in leukemia and lymphoma. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Homo-Delarche.  Glucocorticoid receptors and steroid sensitivity in normal and neoplastic human lymphoid tissues: a review. , 1984, Cancer research.

[20]  M. Lippman.  Steroids in malignant diseases: progress in patient selection. , 1984, Hospital practice.

[21]  C. Bird,et al.  Prednisolone levels in plasma and leukemia cells during therapy of chronic lymphocytic leukemia. , 1984, Journal of pharmaceutical sciences.

[22]  M. Zimmermann,et al.  Guidelines for therapy of pain in cancer patients. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[23]  T. Walsh,et al.  Hospice care: the treatment of pain in advanced cancer. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[24]  J. Vaquero,et al.  Primary cerebral lymphoma: the "ghost tumor". Case report. , 1984, Journal of neurosurgery.

[25]  C. Moertel.  Treatment of the carcinoid tumor and the malignant carcinoid syndrome. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G. Hanks,et al.  Corticosteroids in terminal cancer--a prospective analysis of current practice. , 1983, Postgraduate medical journal.

[27]  R. Fisher,et al.  Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. , 1983, Annals of internal medicine.

[28]  A. F. Stewart.  Therapy of malignancy-associated hypercalcemia: 1983. , 1983, The American journal of medicine.

[29]  J. Cawley,et al.  Glucocorticoid binding and cytolethal responsiveness of hairy-cell and chronic lymphocytic leukaemia. , 2008, Clinical and laboratory haematology.

[30]  J. Armitage,et al.  Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) , 1982, Cancer.

[31]  P. Band,et al.  Comparison of induction chemotherapies for metastatic breast cancer. An eastern cooperative oncology group trial , 1982, Cancer.

[32]  M. Pasmantier,et al.  Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. , 1982, Annals of internal medicine.

[33]  R. Baron,et al.  Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. , 1982, The Journal of clinical endocrinology and metabolism.

[34]  J. Posner,et al.  Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients , 1982, Cancer.

[35]  R. K. Knight,et al.  Corticosteroids for elderly patients with breast cancer , 1981, Cancer.

[36]  H. B. Shumacker.  Management of moderate lymphedema. , 1981, Archives of surgery.

[37]  F. Bochner,et al.  Intraoperative pharmacokinetics of dexamethasone. , 1981, British journal of clinical pharmacology.

[38]  J. Posner,et al.  Epidural spinal cord compression from metastatic tumor: Results with a new treatment protocol , 1980, Annals of neurology.

[39]  G. Mundy,et al.  Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy. , 1980, Annals of internal medicine.

[40]  V. Ventafridda,et al.  The continuing care of terminal cancer patients : proceedings of an International Seminar on Continuing Care of Terminal Cancer Patients, Milan, 19-20 October 1979 , 1980 .

[41]  M E Pickup,et al.  Clinical Pharmacokinetics of Prednisone and Prednisolone , 1979, Clinical pharmacokinetics.

[42]  L. Stern,et al.  Steroid myopathy. , 2020, Arizona medicine.

[43]  J. Posner.  Neurologic complications of systemic cancer. , 1978, Disease-a-month : DM.

[44]  T. Lister,et al.  MVPP chemotherapy regimen for advanced Hodgkin's disease , 1978, British medical journal.

[45]  L. Sherwood,et al.  6 – Disorders of Mineral Metabolism in Malignancy , 1978 .

[46]  C. Presant,et al.  Management of superior vena cava syndrome. , 1978, Seminars in oncology.

[47]  A. Meikle,et al.  Effectiveness of prednisolone during phenytoin therapy , 1977, Clinical pharmacology and therapeutics.

[48]  Erwin K. Kastrup,et al.  Drug facts and comparisons , 1977 .

[49]  G. Humphrey,et al.  Combination intrathecal therapy for meningeal leukemia: two versus three drugs. , 1977, Blood.

[50]  S. Rosenberg,et al.  Prednisone in MOPP chemotherapy for Hodgkin's disease. , 1976, British medical journal.

[51]  V. Devita,et al.  Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. , 1976, Annals of internal medicine.

[52]  F. H. Tyler,et al.  Kinetics and interconversion of prednisolone and prednisone studied with new radioimmunogassays. , 1975, The Journal of clinical endocrinology and metabolism.

[53]  F. Wilner,et al.  Combination chemotherapy in the treatment of advanced Hodgkin's disease. , 1975, Michigan medicine.

[54]  M. D. Shanklin,et al.  Value of prednisone in combination chemotherapy of stage IV Hodgkin's disease. Report from the British National Lymphoma Investigation. , 1975, British medical journal.

[55]  R. Hahn,et al.  Corticosteroid therapy of preterminal gastrointestinal cancer , 1974, Cancer.

[56]  H. Kehlet,et al.  Adrenocortical function and clinical course during and after surgery in unsupplemented glucocorticoid-treated patients. , 1973, British journal of anaesthesia.

[57]  E. Boldrey,et al.  Dose dependency of decadron in patients with partially excised brain tumors. , 1973, Journal of neurosurgery.

[58]  E. Ezdinli,et al.  Chlorambucil vs. combined chlorambucil‐corticosteroid therapy in chronic lymphocytic leukemia , 1973, Cancer.

[59]  L. Powell,et al.  Corticosteroids in liver disease: Studies on the biological conversion of prednisone to prednisolone and plasma protein binding , 1972, Gut.

[60]  H. Goodpasture,et al.  Clinical correlations during amphotericin B therapy. , 1972, The Journal of the Kansas Medical Society.

[61]  M. Koenig,et al.  Reversible cardiac enlargement during treatment with amphotericin B and hydrocortisone. Report of three cases. , 1971, The American review of respiratory disease.

[62]  A. J. Donovan,et al.  Osseous metastasis in mammary cancer. Response to therapy. , 1970, Archives of surgery.

[63]  H. Wilson,et al.  Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. , 1969, JAMA.

[64]  E. Ezdinli,et al.  Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia , 1969, Cancer.

[65]  J. Wolff,et al.  Varying prednisone dosage in remission induction of previously untreated childhood leukemia , 1968, Cancer.

[66]  J. Wolff,et al.  Prednisone therapy of acute childhood leukemia: prognosis and duration of response in 330 treated patients. , 1967, The Journal of pediatrics.

[67]  H. F. West.  The Adrenal Cortex in Internal Medicine , 1966 .

[68]  G. Mathé,et al.  Extensive Histological and Cytological Survey of Patients with Acute Leukaemia in “Complete Remission”* , 1966, British medical journal.

[69]  T. Vietti,et al.  THE RESPONSE OF ACUTE CHILDHOOD LEUKEMIA TO AN INITIAL AND A SECOND COURSE OF PREDNISONE. , 1965, The Journal of pediatrics.

[70]  J. Galicich,et al.  THE USE OF STEROIDS FOR CONTROL OF CEREBRAL EDEMA. , 1964, Clinical neurosurgery.

[71]  E. Frei,et al.  A Study of Prednisone Therapy in Chronic Lymphocytic Leukemia , 1961 .

[72]  B. Stoll.  Dexamethasone in advanced breast cancer , 1960, Cancer.

[73]  D. Hammond,et al.  Prednisone in childhood leukemia; comparison of interrupted with continuous therapy. , 1959, Pediatrics.

[74]  E. Cohen.  [Adrenal cortical hormones]. , 1952, Pharmaceutisch weekblad.

[75]  F. J. Heck,et al.  Cortisone and ACTH in the management of leukemia and lymphoblastoma. , 1950, Proceedings of the staff meetings. Mayo Clinic.

[76]  C. P. Rhoads,et al.  Acth‐ and cortisone‐induced regression of lymphoid tumors in man. A preliminary report , 1949 .

[77]  A. White,et al.  Effect of Pituitary Adrenotropic Hormone on Lymphoid Tissue.∗ , 1943 .